The FDA’s new Quality Management System Regulation (QMSR) comes into effect on 2nd February, 2026, and it brings a clear message for the medical device and pharmaceutical industries: manual systems are no longer sufficient. As regulatory expectations rise, organizations relying on spreadsheets, paper logs, or disconnected tools will struggle to keep pace with the new compliance requirements.
Traditionally, Real-Time Location Systems (RTLS) have been viewed mainly as tools for improving warehouse efficiency or basic asset tracking. However, this narrow use case misses the broader compliance challenges faced by regulated industries. In highly controlled environments, simply knowing where an asset is located does not meet regulatory expectations. What matters is documented, auditable proof of process control, traceability, and system-driven accountability.
Under the new QMSR framework, organizations must demonstrate tighter control over assets, processes, and quality events. RTLS plays a critical role by moving beyond passive tracking to active compliance enablement. Automated data capture, real-time monitoring, and system-generated records help reduce human error and close gaps that manual processes often leave behind.
By leveraging RTLS, companies can align operations with FDA's new QMSR audit guidelines while also supporting ISO 13485 harmonization requirements. Automated location intelligence ensures that assets are used correctly, remain within approved zones, and follow validated workflows—creating a strong foundation for audit readiness and continuous compliance.
LocaXion’s new eBook explores how RTLS can be strategically implemented to automate FDA compliance, strengthen quality systems, and future-proof operations ahead of 2026. Rather than just tracking assets, organizations can transform RTLS into a compliance-driven solution that supports regulatory confidence and operational resilience.
Sign in to leave a comment.